AbbVie: Balance Is Everything

Summary:

  • AbbVie’s future growth depends on improving its balance of drugs offered, in contrast to its Humira-dependent first decade.
  • Skyrizi and Rinvoq should offset the decline in Humira sales, but further growth depends on oncology and neuroscience as well as international sales growth in aesthetics.
  • Even with this growth, ABBV stock should deliver around 8% total return annually through the end of the decade. This is in line with market performance making AbbVie a hold.

Adalimumab Prescription

Hailshadow

The Decline of Humira

For the first seven years of AbbVie’s (NYSE:ABBV) existence as a public company, its top selling drug Humira made up over 60% of the company’s total sales on average. By some accounts, based on cumulative sales


Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *